Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humatrope ® (somatropin)
Humatrope® (somatropin): Contraindications
Humatrope (somatropin) must not be used when there is any evidence of activity of a tumour. Somatropin should not be used in some patients
Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth.
Humatrope should not be reconstituted with the supplied solvent for patients with a known sensitivity to either metacresol or glycerol.
Humatrope should not be used for growth promotion in children with closed epiphyses.
Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Date of Last Review: February 01, 2019